Artisan Partners Limited Partnership Boosts Position in Glaukos Corporation $GKOS

Artisan Partners Limited Partnership increased its holdings in Glaukos Corporation (NYSE:GKOS) by 2.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 293,665 shares of the medical instruments supplier’s stock after acquiring an additional 6,444 shares during the quarter. Artisan Partners Limited Partnership owned about 0.51% of Glaukos worth $23,948,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in GKOS. AQR Capital Management LLC raised its holdings in Glaukos by 2.6% in the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after purchasing an additional 198 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of Glaukos by 1,405.9% during the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after buying an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Glaukos by 41.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after buying an additional 67,668 shares in the last quarter. AlphaQuest LLC lifted its holdings in Glaukos by 5,754.5% in the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 633 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Glaukos by 72.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 48,439 shares of the medical instruments supplier’s stock valued at $5,003,000 after acquiring an additional 20,401 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Stifel Nicolaus increased their target price on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Wells Fargo & Company increased their price objective on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Citigroup raised their price objective on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. Finally, Needham & Company LLC lifted their price target on shares of Glaukos from $125.00 to $127.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average price target of $133.69.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $120.01 on Friday. The business has a fifty day moving average price of $116.00 and a 200-day moving average price of $100.09. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The company has a market capitalization of $6.97 billion, a PE ratio of -36.81 and a beta of 0.70. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $130.23.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The company had revenue of $143.12 million during the quarter, compared to analysts’ expectations of $132.16 million. During the same period in the prior year, the firm earned ($0.40) EPS. Glaukos’s revenue for the quarter was up 35.6% compared to the same quarter last year. As a group, equities analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Insider Transactions at Glaukos

In related news, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the transaction, the chief executive officer directly owned 153,775 shares in the company, valued at $17,684,125. The trade was a 54.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Aimee S. Weisner sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the completion of the transaction, the director directly owned 18,806 shares in the company, valued at $2,207,448.28. This trade represents a 44.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 325,000 shares of company stock valued at $37,739,259. 5.80% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.